In spite of the wide expression pattern of PLAC1 in variety of cancers, prostate cancer seems to be the prototype model for investigation of potential therapeutic effects of anti-PLAC1-based nanomedicine due to its high prevalence1,31,32 and differential expression of PLAC1 in PCa8,33. The gene discussed is PLAC1; the disease is prostate carcinoma.